Small Molecules

20 Nov 2018 Asceneuron Initiates Neuroimaging Trial for Tau Modifier ASN120290
20 Nov 2018 BELLUS Health Announces Positive Top-Line Phase 1 Results for its Chronic Cough Drug Candidate BLU-5937
20 Nov 2018 Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
19 Nov 2018 GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
19 Nov 2018 Bridge Biotherapeutics Files Investigational New Drug Application for BBT-877, an Autotaxin Inhibitor for Idiopathic Pulmonary Fibrosis
19 Nov 2018 FDA Approves AEMCOLO™ (rifamycin), the First Antibiotic Approved for the Treatment of Travelers' Diarrhea in Over a Decade
19 Nov 2018 Aeterna Zentaris (AEZS) Receives Positive CHMP Opinion of Macimorelin for Diagnosis of Adult Growth Hormone Deficiency
19 Nov 2018 TRACON Pharmaceuticals Presents Data from Phase 2 Trial of TRC102 and Temodar® in Patients with Recurrent Glioblastoma at Society for Neuro-Oncology Annual Meeting
19 Nov 2018 Corcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant to Treat Patients with Cushing’s Syndrome
18 Nov 2018 Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
18 Nov 2018 European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
18 Nov 2018 Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease
18 Nov 2018 Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
18 Nov 2018 FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
16 Nov 2018 Tolero Pharmaceuticals Presents Clinical Data of AXL Kinase Inhibitor TP-0903 Showing its Ability to Enhance Host Immune Responses to Tumors
16 Nov 2018 Vyera Pharmaceuticals Receives FDA Clearance To Initiate A Phase 1 Study Of A New Chemical Entity Designed As A Potential Treatment For Toxoplasmosis
16 Nov 2018 Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China
15 Nov 2018 Constellation Pharmaceuticals Highlights EZH2 Inhibition Program in Prostate Cancer at Biomedical Conference
15 Nov 2018 European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib
15 Nov 2018 Pharmaxis releases positive results of phase 1 clinical trial for second LOXL2 inhibitor compound
14 Nov 2018 Acquist Presents Positive Results for Its Lead NASH Drug, ACQT1127, at The Liver Meeting®
14 Nov 2018 Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache
14 Nov 2018 Attenua Announces First Patient Treated in Phase 2 Clinical Trial in Chronic Cough with Bradanicline
14 Nov 2018 Janssen Seeks Expanded Use of IMBRUVICA®▼ (ibrutinib) in Two Indications in Europe
13 Nov 2018 Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR Symposium

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up